Nov 23, 2021
[3 min Read]
ZM-017 & ZM-020 news around the corner
Patents are near completion, Board member buys 250k shares at 45 cents. over 35 files filed on November 22,23,24.
US20210156839 - COMPOSITIONS AND METHODS FOR DIAGNOSING PARASITIC INFECTIONS
Grant Date 31.08.2021
US20200172979 COMPOSITIONS AND METHODS FOR IDENTIFYING CANCER
WO2021007007 - COMPOSITIONS AND METHODS FOR DIAGNOSING URINARY TRACT INFECTIONS
WO2021016552 - N-CADHERIN BINDING MOLECULES AND USES THEREOF
Q4,Q1 Zomedica will be beating earnings with PulseVet Rev.
Key Points Golden Cross Weekly/2-4HR Charts
•Zomedica Corp current quarter revenue growth YoY of 123.40% ranked 438 out of 5660 companies
•Weekly/2-4HR Golden Cross.
•The R&D expenses reached $0.3M, implying a ~89% decline with the completion of TRUFORMA development. However, SG&A expenses soared ~165% YoY to $6.1M, driven by a $1.5M share-based compensation expense during the period.
•09/2020 144 units placed is more then 2x Last Quarter.
•Earning don't mean shit until they do
•Paperhands show fear and feed down the social sentiment
•Bots and Algo see this and start putting pressure in this group, Stocktwits, Twitter, in all social media platforms.
•The reasons Zomedica is going to be uptrending and has been for past two month $IWM $IWO, we being pushed and the tree will be shaking on multiple occasions like last night. Micro/Small cap in general is going higher going into 2022.
•To sell afterhours you need a buyer so stop the fear, This is a accumulation tactic even a cover attempt.
•The market is in rotation currently and a lot of hedgies are gonna get fucked with their FTD (Fail to Deliver) liquidations are happening and more to come.
•Citadel Closed its full position in @Zomedica on 08/16
•Citadel was charged in RICO case for racketeering on 08/17
•Zomedica is targeting VetCor Banfield Pet Hospital VCA Animal Hospitals
•Share Buy backs are trending current shorts hold 120m in shares I expect Zomedica to buy 100M in shares for under 60M
•ZM-017 Patent is in Final Stages 10/21
•ZM-020 mentioned in Q3 10-k last night
•Larry Heaton used a keyword in his report saying Pulsevet was the “FIRST” acquisition by Zomedica.
•2022 Global Sales Expansion
•200M in Cash Reserves [War Chest]
•50 cents been a key support since 2017 [IPO], should say a lot with current share buy back trend, R/S impossible, moving the company is impossible to Delaware we should see 50/60M dollar buy back by Zomedica because they won't have this chance again and not like last time they actually have the extra funds to do it and acquire another company with approximately 5 years of funding still left in their War Chest for expenses, r&d, employees
•Cash Flow positive by 2023
•Our true valuation in 2023 should be around 40 Billion with full diagnostic pipeline with current float should put your Price Target on Zomedica in 2023 at $40 a share
•Valuations don't matter until they do, earnings don't matter until they do, Citadel short laddered the stock down with a bunch of other “MEME” stocks.. they all run the same Algo as I said in April of 2020. Don't let the FUD scare you!
•2020 4400% gains from 6 cents to $2.80, if we get those same numbers it's $20 a share.. $5/6 is a healthy target!
•Zomedica isn't only going to compete but it will complete the veterinary sector.
•130k Followers on Stocktwits, 380k on Webull a lot of eye on Zomedica.
•Citadel has ownership in Facebook, Stocktwits, Twitter they have eyes and bots everywhere and their one of many short sellers that have bots on social platforms debunking Zomedica. They pay stock media outlets to release articles that benefit them because it also benefits their investors which is JP, Vanguard, BlackRock as they take advantage by averaging down on their Long Term positions as seen after April very heavy institutional sentiment going into Q2 & Q3.